Unlock instant, AI-driven research and patent intelligence for your innovation.

Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

a polyalkylene glycol and conjugate technology, applied in the field of drug-oligomer conjugates, can solve the problems of low dosage requirements, achieve the effects of reducing inter-subject variability, reducing degradation, and increasing in vivo activity

Inactive Publication Date: 2006-07-13
BIOCON LTD
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a mixture of drug-oligomer conjugates that have higher in vivo activity and lower dosage requirements than a polydispersed mixture of similar conjugates. The mixture also has better resistance to degradation and lower inter-subject variability. The drug-oligomer conjugates are monodispersed and include a polyalkylene glycol moiety with at least two polyalkylene glycol subunits. The mixture has a molecular weight distribution with a standard deviation of less than about 22 Daltons and a dispersity coefficient of greater than 10,000. The invention also provides a mixture of conjugates with the same number of polyalkylene glycol subunits and the same molecular weight.

Problems solved by technology

This heightened activity may result in lower dosage requirements.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
  • Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
  • Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

Examples

Experimental program
Comparison scheme
Effect test

examples 1 through 10

[0388] Reactions in Examples 1 through 10 were carried out under nitrogen with magnetic stirring, unless otherwise specified. “Work-up” denotes extraction with an organic solvent, washing of the organic phase with saturated NaCl solution, drying (MgSO4), and evaporation (rotary evaporator). Thin layer chromatography was conducted with Merck glass plates precoated with silica gel 60° F.-254 and spots were visualized by iodine vapor. All mass spectra were determined by Macromolecular Resources Colorado State University, CO and are reported in the order m / z, (relative intensity). Elemental analyses and melting points were performed by Galbraith Laboratories, Inc., Knoxville, Tenn. Examples 1-10 refer to the scheme illustrated in FIG. 2.

example 1

8-Methoxy-1-(methylsulfonyl)oxy-3,6-dioxaoctane (9)

[0389] A solution of non-polydispersed triethylene glycol monomethyl ether molecules (4.00 mL, 4.19 g, 25.5 mmol) and triethylamine (4.26 mL, 3.09 g, 30.6 mmol) in dry dichloromethane (50 mL) was chilled in an ice bath and place under a nitrogen atmosphere. A solution of methanesulfonyl chloride (2.37 mL, 3.51 g, 30.6 mmol) in dry dichloromethane (20 mL) was added dropwise from an addition funnel. Ten minutes after the completion of the chloride addition, the reaction mixture was removed from the ice bath and allowed to come to room temperature. The mixture was stirred for an additional hour, at which time TLC (CHCl3 with 15% MEOH as the elutant) showed no remaining triethylene glycol monomethyl ether.

[0390] The reaction mixture was diluted with another 75 mL of dichloromethane and washed successively with saturated NaHCO3, water and brine. The organics were dried over Na2SO4, filtered and concentrated in vacuo to give a non-polyd...

example 2

Ethylene Glycol Mono Methyl Ether (10) (m=4,5,6)

[0391] To a stirred solution of non-polydispersed compound 11 (35.7 mmol) in dry DMF (25.7 mL), under N2 was added in portion a 60% dispersion of NaH in mineral oil, and the mixture was stirred at room temperature for 1 hour. To this salt 12 was added a solution of non-polydispersed mesylate 9 (23.36) in dry DMF (4 ml) in a single portion, and the mixture was stirred at room temperature for 3.5 hours. Progress of the reaction was monitored by TLC (12% CH3OH—CHCl3). The reaction mixture was diluted with an equal amount of 1N HCl, and extracted with ethyl acetate (2×20 ml) and discarded. Extraction of aqueous solution and work-up gave non-polydispersed polymer 10 (82-84% yield).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

A non-polydispersed mixture of conjugates in which each conjugate in the mixture comprises a drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugates. The mixture may be more effective at surviving an in vitro model of intestinal digestion than polydispersed mixtures of similar conjugates. The mixture may result in less inter-subject variability than polydispersed mixtures of similar conjugates.

Description

FIELD OF THE INVENTION [0001] The present invention relates to drug-oligomer conjugates. BACKGROUND OF THE INVENTION [0002] Pharmaceutically active molecules such as proteins and polypeptides have been conjugated with polydispersed mixtures of polyethylene glycol or polydispersed mixtures of polyethylene glycol containing polymers to provide polydispersed mixtures of drug-oligomer conjugates. For example, U.S. Pat. No. 4,179,337 to Davis et al. proposes conjugating polypeptides such as insulin with various polyethylene glycols such as MPEG-1900 and MPEG-5000 supplied by Union Carbide. [0003] U.S. Pat. No. 5,567,422 to Greenwald proposes the conjugation of biologically active nucleophiles with polyethylene glycols such as m-PEG-OH (Union Carbide), which has a number average molecular weight of 5,000 Daltons. [0004] U.S. Pat. No. 5,405,877 to Greenwald et al. proposes reacting bovine hemoglobin with thiazolidine thione activated PEG, which was prepared using m-PEG carboxylic acid havi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/22A61K38/19A61K38/16A61K38/00A61K39/385A61K47/34A61K47/48A61P5/00A61P43/00C07K1/107
CPCA61K39/385A61K47/48215A61K2039/6093C07K1/1077A61K47/60A61P5/00A61P43/00
Inventor EKWURIBE, NNOCHIRI N.
Owner BIOCON LTD